Breaking News Instant updates and real-time market news.

EPD

Enterprise Products

$29.23

0.02 (0.07%)

, HMNY

Helios and Matheson

$0.08

0.014 (20.09%)

08:45
08/07/18
08/07
08:45
08/07/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Enterprise Products (EPD) 2.88% +0.40, Helios and Matheson (HMNY) 107.88% +0.19, Bilibili (BILI) 34.03% +0.15, NXP Semiconductors (NXPI) 0.40% +0.15, Brookfield Property (BPY) 47.18% +0.07, Hi Crush (HCLP) 5.78% +0.06, ProShares Short VIX Short Term Futures (SVXY) 1.17% +0.03, Majesco (COOL) 44.01% +0.03, Macquarie Infrastructure (MIC) 0.41% +0.02, and Direxion Daily China Bull 3X Shares (YINN) 5.95% +0.01.

EPD

Enterprise Products

$29.23

0.02 (0.07%)

HMNY

Helios and Matheson

$0.08

0.014 (20.09%)

BILI

Bilibili

$11.26

0.22 (1.99%)

NXPI

NXP Semiconductors

$96.26

0.34 (0.35%)

BPY

Brookfield Property

$20.52

0.23 (1.13%)

HCLP

Hi-Crush Partners

$13.10

-0.15 (-1.13%)

SVXY

ProShares Short VIX Short-Term Futures

$14.24

0.255 (1.82%)

COOL

Ticker changed to PTE

$20.41

-0.5 (-2.39%)

MIC

Macquarie Infrastructure

$45.95

0.02 (0.04%)

  • 07

    Aug

  • 27

    Aug

  • 11

    Sep

  • 12

    Sep

EPD Enterprise Products
$29.23

0.02 (0.07%)

08/01/18
MUFG
08/01/18
NO CHANGE
Target $35
MUFG
Overweight
Enterprise Products price target raised to $35 from $31 at MUFG
MUFG analyst Barrett Blaschke raised his price target on Enterprise Products to $35 and kept his Overweight rating after its Q2 saw above-consensus EBITDA and cash flows. The analyst also cites a "more supportive commodity price environment" and contribution coming from several new projects, along with a "healthy" amount of leverage for the company.
04/25/18
04/25/18
INITIATION

Enterprise Products initiated with a Buy at JonesTrading
JonesTrading analyst Eduardo Seda started Enterprise Products Partners with a Buy rating and $34 price target. The company's lower risk, fee-based business model provides stable cash flow generation and distribution stability, Seda tells investors in a research note.
03/21/18
MUFG
03/21/18
NO CHANGE
MUFG
'Indiscriminate' selling in midstream MLPs presents opportunity, says MUFG
MUFG analyst Barrett Blaschke attributes a pair of recent announcements from FERC for the broad selloff that has followed in midstream MLPs. He notes that on March 15, FERC ruled that MLPs can no longer use an income tax allowance in their rate calculation and also proposed a rate adjustment to account for the reduction in the corporate tax rate. This has led to "indiscriminate panic selling" across the space, which he sees as a buying opportunity "at what may be effectively fire-sale prices," he tells investors. Blaschke notes that Antero Midstream Partners (AM), Antero Midstream GP (AMGP), Hess Midstream Partners (HESM) and Noble Midstream (NBLX), on which he has Overweight ratings, "effectively have no assets impacted by the change." The analyst also points toward Enterprise Products (EPD), EQT Midstream Partners (EQM), MPLX (MPLX), Phillips 66 Partners (PSXP) and Valero Energy Partners (VLP) as likely to be only minimally impacted by the ruling.
04/19/18
DBAB
04/19/18
INITIATION
Target $31
DBAB
Buy
Enterprise Products initiated with a Buy at Deutsche Bank
Deutsche Bank started Enterprise Products Partners with a Buy rating and $31 price target.
HMNY Helios and Matheson
$0.08

0.014 (20.09%)

04/25/18
MAXM
04/25/18
INITIATION
Target $12
MAXM
Buy
Helios and Matheson assumed with a Buy at Maxim
Maxim analyst Nehal Chokshi assumed Helios and Matheson with a Buy rating but lowered his price target to $12 from $16 under the prior coverage. The analyst contends that survey findings suggest "overusage being contained to a sliver of subscribers" and believes the company can trade at $12 per share based on enterprise value of $1.4B is its MoviePass offering can show incremental traffic from occasional movie goers hitting just 1 movie ticket per month.
07/26/18
MAXM
07/26/18
INITIATION
MAXM
Hold
Helios and Matheson assumed with a Hold at Maxim
Maxim analyst Allen Klee assumed Helios and Matheson with a Hold rating, saying that while he remains optimistic about the potential for continued MoviePass subscriber growth, he is also cautious about the company's potential capital raising needs. Klee also sees the stock as a "high risk/reward" situation as it trades at 0.1-times his expected FY18 revenue estimate.
07/29/18
EROP
07/29/18
DOWNGRADE
EROP
Neutral
Helios and Matheson downgraded to Neutral from Buy at Euro Pacific
04/24/18
ADAM
04/24/18
NO CHANGE
Target $12
ADAM
Buy
Helios and Matheson price target lowered to $12 from $15 at Canaccord
Canaccord analyst Austin Moldow lowered his price target on Helios and Matheson to $12 from $15 following its recent capital raise. The analyst raised his revenue forecast, but it was more than offset by the higher share count given the company's capital raise and its at-the-market offering, where the company can sell shares in the open market at its discretion. Moldow maintained his Buy rating on Helios and Matheson shares.
BILI Bilibili
$11.26

0.22 (1.99%)

04/23/18
MSCO
04/23/18
INITIATION
Target $13.7
MSCO
Overweight
Bilibili initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Alex Poon started Bilibili with an Overweight rating and $13.70 price target as he likes its niche focus on China's younger generations and multiple monetization pillars to drive stronger revenue and margin growth than peers.
04/26/18
BOFA
04/26/18
INITIATION
Target $13
BOFA
Buy
Bilibili initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Binnie Wong initiated Bilibili with a Buy and $13 price target. The analyst is constructive on Bilibili's ability to promote a social gaming community with highly engaged viewers and content creators in the niche animation, comics, and games online video market.
05/07/18
05/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with an Outperform at Telsey Advisory. 2. Zuora (ZUO) initiated with a Buy at Needham and Jefferies, an Equal Weight at Morgan Stanley, and a Neutral at Goldman Sachs. 3. Bilibili (BILI) initiated with an Overweight at JPMorgan. 4. Cloudera (CLDR) initiated with a Buy at Craig-Hallum. 5. Scynexis (SCYX) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/07/18
JPMS
05/07/18
INITIATION
Target $14
JPMS
Overweight
Bilibili initiated with an Overweight at JPMorgan
JPMorgan analyst Alex Yao started Bilibili with an Overweight rating and $14 price target. The company is an "undisputed vertical leader" among video content platforms targeting Generation Z, with "unique social features and rich content library" in animation, comics and gaming, Yao tells investors in a research note. He believes Bilibili's "multifaceted" revenue models are at the early development stage.
NXPI NXP Semiconductors
$96.26

0.34 (0.35%)

08/02/18
LEHM
08/02/18
INITIATION
Target $100
LEHM
Equal Weight
NXP Semiconductors reinstated with an Equal Weight at Barclays
Barclays analyst Blayne Curtis reinstated coverage of NXP Semiconductors with an Equal Weight rating and $100 price target. The analyst sees "too much uncertainty on the top and bottom line" for a more constructive rating at this time. He believes NXP shares will trade at a discount to "higher quality" analog peers.
08/02/18
08/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Magnolia Oil & Gas (MGY) initiated with a Buy at SunTrust. 2. VICI Properties (VICI) initiated with a Neutral at Citi. 3. Cision (CISN) initiated with a Buy at Citi. 4. Allena Pharmaceuticals (ALNA) initiated with a Buy at Ladenburg. 5. NXP Semiconductors (NXPI) reinstated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/18
NEED
07/30/18
NO CHANGE
Target $120
NEED
Strong Buy
NXP Semiconductors price target lowered to $120 from $130 at Needham
Needham analyst Rajvindra Gill lowered his price target on NXP Semiconductors (NXPI) to $120 to reflect last week's sell-off that followed its earnings, buyback, and terminated Qualcomm (QCOM) deal. The analyst also keeps his Strong Buy rating and believes that investors will re-evaluated the shares, given that the company's revenue mix is much healthier on combination of auto, industrial and internet of things end markets, while the revenues lost from ZTE (ZTCOY) component import ban should resume in Q3.
07/27/18
07/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) reinstated with a Neutral at BofA/Merrill. 2. uniQure (QURE) initiated with an Overweight at Cantor Fitzgerald. 3. Autolus Therapeutics (AUTL) initiated with a Neutral at Goldman Sachs. 4. Pure Storage (PSTG) initiated with an Overweight at JPMorgan. 5. Plains All American (PAA) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BPY Brookfield Property
$20.52

0.23 (1.13%)

03/27/18
ADAM
03/27/18
UPGRADE
ADAM
Buy
Brookfield Property upgraded to Buy from Hold at Canaccord
03/27/18
JPMS
03/27/18
DOWNGRADE
Target $23.5
JPMS
Neutral
GGP downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Mueller downgraded GGP (GGP) to Neutral and lowered his price target for the shares to $23.50 from $25.50. The analyst is shuffling his ratings in the REIT space following GGP's takeout by Brookfield Property Partners (BPY). He believes the price paid by Brookfield makes his "bullish mall thesis harder to push."
03/27/18
RHCO
03/27/18
DOWNGRADE
Target $23.5
RHCO
Hold
GGP downgraded to Hold from Buy at SunTrust
SunTrust analyst Ki Bin Kim downgraded GGP (GGP) to Hold from Buy and lowered the price target to $23.50 from $26 after Brookfield Property Partners (BPY) agreed to acquire the company at that price. While the improved offer represents only a "half-step" forward toward more equitable valuation relative to prior approach, the analyst ultimately expects this deal to close.
03/27/18
03/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. BB&T (BBT) upgraded to Buy from Neutral at B. Riley FBR and to Outperform from Market Perform at Wells Fargo. 2. Aratana Therapeutics (PETX) upgraded to Buy from Hold at Stifel with analyst Jonathan Block saying the early traction for Entyce, which was launched October 2017, has increased his conviction that the drug will act as the main revenue driver for Aratana in coming years. 3. Prologis (PLD) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Mueller saying he is shuffling his ratings in the REIT space following GGP's (GGP) takeout by Brookfield Property Partners (BPY). 4. Brookfield Property (BPY) upgraded to Buy from Hold at Canaccord. 5. Roku (ROKU) upgraded to Neutral from Sell at Citi with analyst Mark May citing valuation for the upgrade following the stock's recent underperformance, but admits the upcoming lock-up expiration could serve as a negative catalyst. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HCLP Hi-Crush Partners
$13.10

-0.15 (-1.13%)

07/30/18
COWN
07/30/18
DOWNGRADE
Target $16
COWN
Market Perform
Hi-Crush Partners downgraded at Cowen on valuation, borrowing potential
As reported previously, Cowen analyst Marc Bianchi downgraded Hi-Crush Partners to Market Perform from Outperform. The analyst cited valuation and its 40% move in the shares as the reason for the downgrade. He also notes the company may need to borrow from its credit facility to pay its dividend if his assumption of industry sand margin compression proves correct. Bianchi has a $16 price target on Hi-Crush Partners shares.
08/07/18
PIPR
08/07/18
DOWNGRADE
Target $14.15
PIPR
Neutral
Hi-Crush Partners downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst John Watson downgraded Hi-Crush Partners to Neutral while raising his price target for the shares to $14.15 from $14. The analyst cites valuation for the downgrade following the stock's rally since the distribution increase in July. Watson says he continues to have confidence in management, however.
08/06/18
SPHN
08/06/18
DOWNGRADE
SPHN
Equal Weight
Hi-Crush Partners downgraded to Equal Weight from Overweight at Stephens
08/06/18
08/06/18
DOWNGRADE
Target $13

Equal Weight
Hi-Crush Partners downgraded to Equal Weight with $13 target at Stephens
As previously reported, Stephens analyst Tommy Moll downgraded Hi-Crush Partners to Equal Weight from Overweight citing the lack of visibility into the company's long-term capital allocation priorities given the range of outcomes regarding dividends, taxes and shareholder dilution after a potential C-corp conversion. He also notes the stock has risen 22% since Hi-Crush announced mine expansion plans, the acquisition o FB Industries, the refinancing of the $200M term loan and the increasing of its quarterly distribution. Moll lowered his price target on Hi-Crush shares to $13 from $16.
SVXY ProShares Short VIX Short-Term Futures
$14.24

0.255 (1.82%)

COOL Ticker changed to PTE
$20.41

-0.5 (-2.39%)

06/27/18
CANT
06/27/18
NO CHANGE
Target $65
CANT
Overweight
Cantor says PolarityTE patent process ongoing, commercialization maturing
After hosting a conference call with PolarityTE management yesterday, Cantor Fitzgerald analyst Elemer Piros said that the company walked through the process of its interaction with the USPTO and explained that the patent process is ongoing, not finalized, and may take years. Meanwhile, SkinTE was commercialized in December 2017 via a limited market release and the company's commercialization efforts are maturing, said Piros, who reiterates an Overweight rating and $65 price target on PolarityTE shares.
06/25/18
CANT
06/25/18
NO CHANGE
Target $65
CANT
Overweight
Cantor reiterates Overweight rating on PolarityTE after meeting with doctors
After attending an event hosted by PolarityTE with Key Opinion Leaders and hearing three surgeons describe their clinical experiences using SkinTE, Cantor Fitzgerald analyst Elemer Piros said he believes PolarityTE is positioned long-term to "redefine the treatment landscape for wound regeneration." He believes the fact that the shares are trading down 33% may be due to the market's misunderstanding of the company's IP strategy and interaction with the U.S. Patent and Trademark Office. Piros' note to investors makes no mention of Citron Research, which earlier today accused PolarityTE of fraud related to its patent holdings and promotion of the patents to investors. Piros reiterates his Overweight rating and $65 price target on PolarityTE, which is down 32% to $26.42 in afternoon trading.
06/13/18
CANT
06/13/18
NO CHANGE
Target $65
CANT
Overweight
PolarityTE price target lowered to $65 from $70 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for PolarityTE to $65 to reflect the company's recent financing. The analyst, however, left an investor tour at the company's Salt Lake City facilities with significant confidence for its "extensive" pipeline. The analyst believes PolarityTE looks well positioned to deliver on its objectives over the next 24 months. He reiterates an Overweight rating on the shares.
02/15/18
02/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Portland General Electric (POR) initiated with a Buy at Mizuho. 2. Arsanis (ASNS) initiated with an Overweight at Cantor Fitzgerald. 3. Cantor says PolarityTE (COOL) can revolutionize regenerative medicine. 4. Foundation Medicine (FMI) initiated with an Outperform at Cowen. 5. Box (BOX) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MIC Macquarie Infrastructure
$45.95

0.02 (0.04%)

02/23/18
RBCM
02/23/18
NO CHANGE
Target $55
RBCM
Outperform
Macquarie Infrastructure price target lowered to $55 from $80 at RBC Capital
RBC Capital analyst TJ Schultz lowers his price target on Macquarie Infrastructure to $55, saying investors were caught off guard by certain St. Rose terminal customers not renewing contracts for heavy oil, which led to the company's 31% dividend cut. The analyst keeps his Outperform rating however, adding that Macquarie Infrastructure's execution could prove that the most recent selloff was too extreme.
02/23/18
WELS
02/23/18
DOWNGRADE
Target $45
WELS
Market Perform
Wells Fargo downgrades Macquarie Infrastructure despite 41% pullback yesterday
Wells Fargo analyst Jonathan Reeder downgraded Macquarie Infrastructure to Market Perform from Outperform and cut his price target for the shares to $45 from $80. The stock closed yesterday down 41%, or $26.21, to $37.41. The analyst says he struggles to come up with a near- or even intermediate-term catalyst that would cause investors to buy into the" revamped story." New CEO Christopher Frost finds himself in a "show me" situation as investors are likely to adopt a wait-and- see approach, Reeder tells investors in a research note after the company cut its dividend. The analyst believes, however, that Macquarie Infrastructure shares could still be worth $55-$60 if management can execute on the newly laid out strategy.
02/23/18
WELS
02/23/18
DOWNGRADE
WELS
Market Perform
Macquarie Infrastructure downgraded to Market Perform at Wells Fargo
02/22/18
02/22/18
NO CHANGE

Macquarie Infrastructure shares oversold, says Oppenheimer
Oppenheimer analyst Ian Zaffino noted that Macquarie Infrastructure shares are trading down 38% since the company announced its dividend cut. Zaffino said, after the company's conference call, that he believes shares are now oversold, and maintained his Buy rating, although he cut his price target on Macquarie intra-day to $60 from $75, after cutting it earlier in the day to $75 from $100.

TODAY'S FREE FLY STORIES

CBFV

CB Financial Services

$25.79

(0.00%)

14:42
11/21/18
11/21
14:42
11/21/18
14:42
Hot Stocks
CB Financial Services increases dividend by 4.5% to 23c per share »

CB Financial Services,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$32.94

4.87 (17.35%)

14:28
11/21/18
11/21
14:28
11/21/18
14:28
Hot Stocks
CD&R Group to buy additional shares in Beacon Roofing »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NTN

NTN Buzztime

$2.70

-0.1 (-3.57%)

14:26
11/21/18
11/21
14:26
11/21/18
14:26
Hot Stocks
Northstar reports 10.33% stake in NTN Buzztime »

On November 21, Northstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:23
11/21/18
11/21
14:23
11/21/18
14:23
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a podcast »

The Commodity Futures…

RHHBY

Roche

$0.00

(0.00%)

, ABBV

AbbVie

$85.75

-2.35 (-2.67%)

14:18
11/21/18
11/21
14:18
11/21/18
14:18
Hot Stocks
Roche announces FDA grants accelerated approval for Venclexta combo »

Roche (RHHBY) announced…

RHHBY

Roche

$0.00

(0.00%)

ABBV

AbbVie

$85.75

-2.35 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
11/21/18
11/21
14:17
11/21/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

, RHHBY

Roche

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Hot Stocks
AbbVie says FDA grants accelerated approval to Venclexta-azacitidine combo »

AbbVie (ABBV) announced…

ABBV

AbbVie

$85.70

-2.4 (-2.72%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

  • 03

    Dec

  • 24

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
11/21/18
11/21
14:16
11/21/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$54.99

1.4 (2.61%)

14:15
11/21/18
11/21
14:15
11/21/18
14:15
Periodicals
Martin Sorrell to poach senior executive from WPP, Sky News reports »

Martin Sorrell is to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

TGT

Target

$69.10

0.05 (0.07%)

14:10
11/21/18
11/21
14:10
11/21/18
14:10
Options
Target calls lead puts 3:1 after a big drop in shares »

Target calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

HWBK

Hawthorn Bancshares

$22.71

(0.00%)

14:08
11/21/18
11/21
14:08
11/21/18
14:08
Hot Stocks
Ategra stake in Hawthorn Bancshares falls to 4.97% »

As of November 20, Ategra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAM

I-AM Capital

$10.00

(0.00%)

14:04
11/21/18
11/21
14:04
11/21/18
14:04
Hot Stocks
I-AM Capital announces closing of transaction with SMAAASH Entertainment »

Smaaash Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBD

Banco Bradesco

$9.60

0.23 (2.45%)

14:00
11/21/18
11/21
14:00
11/21/18
14:00
Options
Longer-term put buyer in Banco Bradesco »

Longer-term put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

, SPX

S&P 500

$0.00

(0.00%)

13:56
11/21/18
11/21
13:56
11/21/18
13:56
Periodicals
Hedge funds get battered in October and are down for year, CNBC says »

According to a CNBC…

SPY

SPDR S&P 500 ETF Trust

$266.76

2.64 (1.00%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$5.54

0.07 (1.28%)

13:50
11/21/18
11/21
13:50
11/21/18
13:50
Options
Aggressive call buy in Vipshop »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

13:50
11/21/18
11/21
13:50
11/21/18
13:50
General news
Treasury Action: yields remain only marginally firmer »

Treasury Action: yields…

PFE

Pfizer

$43.23

-0.3 (-0.69%)

13:41
11/21/18
11/21
13:41
11/21/18
13:41
Hot Stocks
Pfizer says FDA approves DAURISMO for adults with newly-diagnosed AML »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

  • 10

    Dec

EFA

iShares MSCI EAFE Index Fund

$62.35

1.05 (1.71%)

13:40
11/21/18
11/21
13:40
11/21/18
13:40
Options
Call buying in iShares Emerging Markets Fund and iShares MSCI EAFA Fund »

Call buying in iShares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

13:30
11/21/18
11/21
13:30
11/21/18
13:30
Options
Vix calls lead puts 4:1 as the index drops 9% »

Vix calls lead puts 4:1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$6.95

0.18 (2.66%)

13:25
11/21/18
11/21
13:25
11/21/18
13:25
Options
Akorn call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

OMED

OncoMed

$1.37

(0.00%)

13:22
11/21/18
11/21
13:22
11/21/18
13:22
Hot Stocks
OncoMed awarded European patent for method for making heteromultimeric molecules 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

, RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Hot Stocks
Aquestive under pressure after generic Suboxone patent decision »

Shares of Aquestive…

AQST

Aquestive Therapeutics

$10.12

-3.05 (-23.16%)

RDY

Dr. Reddy's

$36.37

-0.11 (-0.30%)

MYL

Mylan

$33.29

-0.65 (-1.92%)

ENDP

Endo

$12.39

-0.14 (-1.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

  • 04

    Dec

  • 19

    Jan

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
11/21/18
11/21
13:17
11/21/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
11/21/18
11/21
13:16
11/21/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$12.60

0.3 (2.44%)

, T

AT&T

$30.01

0.6 (2.04%)

13:15
11/21/18
11/21
13:15
11/21/18
13:15
Hot Stocks
GameStop jumps over 10% after agreeing to sell Spring Mobile unit »

Shares of GameStop (GME)…

GME

GameStop

$12.60

0.3 (2.44%)

T

AT&T

$30.01

0.6 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.